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Abstract: The tricarboxylic acid (TCA) cycle is a central part of carbon and energy metabolism,
also connecting to glycolysis, amino acid, and lipid metabolism. The quantitation of the TCA
cycle intermediate within one method is lucrative due to the interest in central carbon metabolism
profiling in cells and tissues. In addition, TCA cycle intermediates in serum have been discovered to
correspond as biomarkers to various underlying pathological conditions. In this work, an Liquid
Chromatography-Mass Spectrometry/Mass Spectrometry-based quantification method is developed
and validated, which takes advantage of fast, specific, sensitive, and cost-efficient precipitation
extraction. Chromatographic separation is achieved while using Atlantis dC18 2.1 mm × 100 mm,
particle size 3-µm of Waters column with a gradient elution mobile phase while using formic acid
in water (0.1% v/v) and acetonitrile. Linearity was clearly seen over a calibration range of: 6.25
to 6400 ng/mL (r2 > 0.980) for malic acid; 11.72 to 12,000 ng/mL (r2 > 0.980) for cis-aconitic acid
and L-aspartic acid; 29.30 to 30,000 ng/mL (r2 > 0.980) for isocitric acid, l-serine, and l-glutamic
acid; 122.07 to 125,000 ng/mL (r2 > 0.980) for citric acid, glycine, oxo-glutaric acid, l-alanine, and
l-glutamine; 527.34 to 540,000 ng/mL (r2 > 0.980) for l-lactic acid; 976.56 to 1,000,000 ng/mL (r2 > 0.980)
for d-glucose; 23.44 to 24,000 ng/mL (r2 > 0.980) for fumaric acid and succinic acid; and, 244.14 to
250,000 ng/mL (r2 > 0.980) for pyruvic acid. Validation was carried out, as per European Medicines
Agency (EMA) “guidelines on bioanalytical method validation”, for linearity, precision, accuracy,
limit of detection (LOD), limit of quantification (LLOQ), recovery, matrix effect, and stability. The
recoveries from serum and tissue were 79–119% and 77–223%, respectively. Using this method, we
measured TCA intermediates in serum, plasma (NIST 1950 SRM), and in mouse liver samples. The
concentration found in NIST SRM 1950 (n = 6) of glycine (246.4 µmol/L), l-alanine (302.4 µmol/L),
and serine (92.9 µmol/L).
Keywords: tricarboxylic acid (TCA) cycle; mass spectrometry; chromatography; metabolites;
bioanalytical method validation
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1. Introduction
The tricarboxylic acid (TCA) cycle or Krebs’ cycle consists of a set of responses active under aerobic
conditions aiming to produce energy in the form of Adenosine triphosphate (ATP). In adding, the TCA
cycle delivers precursors to biosynthesis of certain amino acids and Reduced Nicotinamide Adenine
Dinucleotide (NADH) [1]. Being part of central carbon metabolism the interest in quantifying TCA cycle
metabolites (Supplementary Figure S1) is apparent, e.g., metabolic dependencies and development of
cancer cells or tumor tissues [2,3]. In recent years, the alterations in TCA cycle compounds that are
present in serum have also been investigated to correspond to various underlying pathological or
physiological conditions. The TCA cycle metabolites have been proposed as biomarkers in serum for
e.g., cardiovascular risks [4], leukemia [5], nasopharyngeal carcinoma [6], prostate cancer [7], diabetic
nephropathy [8], and nutritional state [9].
To date, multiple mass spectrometry-based approaches are able to quantitate TCA-cycle related
compounds utilizing various chromatographic techniques, such as gas chromatography using acylation
or silylation of analytes, capillary electrophoresis, and liquid chromatographic (LC) approaches that
are based on ion exchange/exclusion, ion pairing, hydrophilic interaction, or reverse phase. Tan et al.
previously covered the variety of literature examples, with their pros and cons [10]. Many of the TCA
cycle molecules are short chain carboxylic acids, the quantitation of which is generally challenged
by bad retaining in reverse phase chromatographic methods, less sensitivity because of ionization
efficiency, and more suppression of ion using electrospray ionization (ESI) [11]. While considering
workflow fluency for high-throughput analysis and maintaining high precision, various challenges are
present in different approaches, and analysis from blood fluid introduces additional complexity in the
form of matrix effect and ion suppression [12]. Commonly, high variation between replicates can be
observed if no proper internal standard is used, especially inter-samples [13,14].
The traditional approaches to serum pretreatment for Liquid Chromatography-Mass Spectrometry
(LC-MS) analysis comprise phospholipid removal plates, protein precipitation, and liquid-liquid
extraction (LLE) [15]. The presence of endogenous phospholipids in the serum matrix can cause
a matrix effect and ion suppression in the LC-MS methods [16,17]. A readymade sample filter
cartridge provides a cost-efficient approach to remove the phospholipids and precipitate proteins for
compound analysis.
This work presents the development and validation for a method to quantify the TCA cycle related
intermediate compounds with targeted LC-MS/MS in human serum, plasma, kasumi-1 cell, and murine
liver tissue. The method combines protein precipitation with the use of a specific corresponding 13C
isotope internal standard for each analyte, providing a cost efficient method and fast pretreatment
with the potential to provide high-throughput analysis with 96-well plates. The pretreatment was
matched with the readily compatible fast reverse-phase based chromatographic method. Additional
preparation steps, e.g., the evaporation of extraction solvent and reconstitution to eluent, were bypassed,
therefore reducing the organic phase by dilution with the aqueous mobile phase in order to enhance
chromatography [18].
2. Results and Discussion
2.1. Method Development
The (Ultra Performance Liquid Chromatography Mass Spectrometry/Mass Spectrometry (UPLC
MS/MS) method was developed with the use of positive and negative ESI ionization mode. Mass
range of Xevo-TQS triple quadrupole mass spectrometer is 2–2048 m/z. This instrument was calibrated
with solution having masses from 62.9636 to 1764.592, but there is no calibration reference points near
low mass (2 m/z) or near high (2048 m/z). This instrument is not high resolution MS and you cannot
really see any difference and the mass accuracy will be same. Calibration only done in positive mode
and negative mode will use positive mode calibration and mass accuracy. The product ion selection
producing the highest response further makes the selectivity and sensitivity of the method better.
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There difference between Glutamine (147.1 m/z) and Glutamic acid (148.1 m/z) is of 1 m/z. Glutamine
has five carbon atoms, which means that 5% of the carbons are C13 and 95% are C12. The 5% will be
the amount of interference have on the glutamic acid channel, as it is not chromatographically separate
from them and the same will uniformly apply to all sample and standards, so overall there were no
more significant impacts on outcome. However, in pyruvic acid and lactic acid there is difference of 2
m/z, so there is considerably less chance of interference because difference of 2 m/z will be separate
even from isotopic mass range. Various stationary-phases, like Discovery HS FS-3, 3um, 2.1 × 150
mm (no proper separation between Citric acid and Iso citric acid and peak shapes at lower levels
of Glutamic acid, pyruvic acid, Lactic acid, Fumaric acid was poor due to less response and tailing),
ACQUITY UPLC BEH Amide, 2.1 mm × 100 mm, 1.7 µm (poor peak shape for few analytes was
observed with tailing) and mobile-phase compositions (ranging from 10 mM ammonium formate (10
mM ammonium acetate) pH 4: 0.1% Formic acid in Acetonitrile and methanol, 0.1% formic acid in
water: Acetonitrile were tested, and, at last, the most optimal separation, peak shape, and response
were obtained in an Atlantis dC18 2.1 × 100 mm, 3-µ column with 0.1% formic acid in water (v/v),
and an acetonitrile as mobile phase in the gradient elution mode. The stability of standard solutions
stored at −20 ◦C was evaluated over a one-month period. Acetonitrile in 1% formic acid was used as
extraction solution, which was prone to protein precipitation in plasma and compatible with Waters
Ostro 96 well plate 25 mg (Part No. 186005518). This plate serves as two sample extraction techniques
i.e., Protein precipitation and solid phase extraction and the solvent recommended for this plate is 1%
Formic acid in Acetonitrile, which is why extraction solvent is taken as 1% Formic acid in Acetonitrile.
However, the final reconstitution solution was selected as 0.1% formic acid in water because extraction
solvent i.e., 1% Formic acid in Acetonitrile as reconstitution solution is prone to broad peak shape of
few metabolites. In tissue, second extraction solvent (acetonitrile:water, 90:10, 1% formic acid) was
additionally used, because, by increasing water portion of the extraction solvent, it could extract higher
metabolites. Accordingly, this step is just an additional step in tissue to obtain more metabolite extract
from complex tissue sample. Cleaner extracts, good recovery, and low matrix effect for the biological
matrix was observed with the above plate and acetonitrile in 1% formic acid as extraction solvent. An
isotope-labeled internal standard was used to accurate determine any possible loss of metabolites
throughout sample preparation. When using the extraction method that is described above, the matrix
effect was found less often and no affect was found on the results due to the structural match of the
internal standard for almost all metabolites.
2.2. Method Validation
2.2.1. Selectivity and Specificity
There were no significant interference peaks from the matrix components in their respective
retention-time windows, which indicated the acceptability of selectivity and specificity of the TCA
cycle intermediates in our method. Each tissue, cell, and serum-sample was injected by repeating five
times and every peak was confirmed to have only eluted from the target analyte, which indicated that
they are specific to their corresponding MRM transitions. Figures 1 and 2 provide the chromatograms
of the entire 16 TCA cycle intermediates of Blank and QC sample (refer to Supplementary Figure S2).
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Figure 1. Blank chromatogram of tricarboxylic acid (TCA) cycle intermediate.
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Figure 2. (a) Chromatogram of TCA cycle inter ediate; (b) Chromatogram of TCA cycle intermediate;
(c) Chromatogram of TCA cycle intermediate; and, (d) Chromatogram of TCA cycle intermediate.
2.2. . Auto-Sampler Carryover
In general, for the majority of the TCA cycle inter ediates, there was no significant carry over
observed in the blank sample following the high concentration standard (Level 11), which is no greater
than 20% of the lowest standard concentration (Level 1) and 5% for the internal standard. Serine, lactic
acid, and citric acid have carryover of 18%, but it is within the limit. The carryover of succinic acid was
more than 20%. No carryover was observed in the internal standards. Therefore, we can conclude that
the syringe, needle, column, and seal washes were adequate to avoid any sample carryover.
2.2.3. Linearity, Accuracy, and Precision
Each calibration curve was statistically evaluated with respect to slope, intercept, and constructed
while using appropriate and best-fit regression models and 1/x2 weighing factors. The observed
coefficient of determination (r2) value for individually TCA cycle intermediate was higher than 0.99.
The accuracy and precision (within and between (two different days) run) evaluated by measuring the
differ nce back-calculat d con entration and ominal concentrat on of calibr t curve st ndards
and quality cont ol samples (n = 6 rep ic tes) at higher, middl , lower, and lower limit of quantification.
The percent mean ccuracy and coefficient of variance in all three batch s were found within 20%
for the major TCA cycle intermediates, except for malic acid (22%) and glutamic acid (26%) (Tables 1
and 2).
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Table 1. Accuracy, limit of detection (LOD) and limit of quantification (LOQ) results of TCA cycle intermediates.
Analyte % Mean Accuracy
a at Different Standard Concentration Level LoQ
(ng/mL)
LoD
(ng/mL)L-1 L-2 L-3 L-4 L-5 L-6 L-7 L-8 L-9 L-10 L-11
cis-Aconitic acid 85.12 80.24 86.54 81.91 94.99 85.73 99.17 104.58 101.65 99.12 100.07 11.72 8.79
Citric acid 103.38 86.48 90.49 93.10 95.52 104.64 101.99 103.79 103.69 101.25 98.51 122.07 12.21
Fumaric acid 96.42 115.90 97.13 109.16 97.60 101.16 99.09 95.49 95.91 98.73 102.65 23.44 17.58
Isocitric acid 102.28 106.47 135.45 138.34 116.83 103.05 91.41 83.08 86.35 95.54 114.94 29.30 14.65
Malic acid 101.33 86.40 82.40 83.07 101.73 104.68 103.53 105.99 104.21 102.07 97.29 6.25 3.13
Pyruvic acid 98.50 86.14 118.65 108.54 100.45 105.05 99.12 96.39 86.12 81.99 86.57 244.14 183.11
Oxoglutaric acid 99.61 101.24 125.54 108.43 99.51 101.72 99.24 98.11 98.44 98.38 98.45 122.07 61.04
Glycine 104.04 116.45 90.41 86.32 116.92 104.29 101.37 101.97 101.40 102.70 98.06 122.07 61.04
l-Alanine 94.24 109.23 101.87 101.99 105.04 103.66 102.49 99.33 97.90 92.59 91.66 122.07 12.21
l-Serine 97.38 100.70 117.07 107.11 100.20 101.90 99.76 100.26 99.10 91.96 96.08 29.30 2.93
l-Aspartic acid 97.84 95.56 121.37 102.72 101.81 101.74 102.04 102.50 99.70 89.49 92.91 11.72 5.86
l-Glutamine 98.28 99.04 104.86 104.54 104.57 105.26 101.34 99.12 89.24 75.12 63.02 122.07 6.10
l-Glutamic acid 97.16 88.41 108.66 102.11 102.84 96.74 97.30 99.39 100.14 100.13 98.48 29.30 2.93
l-Lactic acid 95.19 109.72 103.53 93.83 97.68 99.92 99.00 99.98 101.23 99.01 100.90 527.34 52.73
Succinic acid 98.98 101.25 104.02 95.32 98.26 101.43 100.23 103.12 102.37 98.57 96.42 23.44 11.72
d-Glucose 96.08 103.03 106.53 104.76 100.91 103.12 102.59 101.29 98.12 94.97 88.60 976.56 97.66
a: % mean accuracy is mean of accuracy of three calibration standard.
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Table 2. Results of recovery, intra- and inter-day precision of TCA cycle intermediates in Serum and Tissue.
Analyte
Linearity
Regression
r2 Value a
Intra-Day Precision of High, Medium
and Low Concentrations, % RSD
Inter-Day Precision of High, Medium
and Low Concentrations, % RSD
Mean
Recovery
Serum (%) b
Mean
Recovery
Tissue (%) b
Mean
Recovery
Cell (%) bHQC MQC LQC HQC MQC LQC
cis-Aconitic acid 0.999 3.83 12.10 14.90 2.73 11.30 15.90 89.30 223.82 107.24
Citric acid 0.993 2.69 5.79 20.24 6.24 5.81 19.84 100.59 125.73 104.36
Fumaric acid 0.995 2.10 5.18 11.63 2.60 5.74 19.34 89.99 77.24 102.54
Isocitric acid 0.990 6.89 11.31 19.57 6.19 17.27 19.82 90.53 111.40 87.04
Malic acid 0.992 1.46 8.61 21.87 1.66 7.56 19.23 104.28 105.66 92.01
Pyruvic acid 0.990 3.36 4.06 14.51 10.86 8.91 12.06 85.00 132.64 91.48
Oxoglutaric acid 0.998 2.17 4.87 11.88 2.66 4.33 11.72 79.93 108.26 86.96
Glycine 0.996 3.20 4.84 17.26 3.95 6.59 19.06 105.34 111.00 108.73
l-Alanine 0.994 2.52 2.68 12.20 2.29 3.54 13.76 106.21 104.72 102.91
l-Serine 0.994 1.95 4.95 11.27 2.58 4.43 16.25 113.68 139.08 104.54
l-Aspartic acid 0.994 6.82 3.27 11.28 5.71 5.13 12.07 107.72 100.49 105.43
l-Glutamine 0.994 3.96 3.55 8.09 4.99 3.38 7.64 113.09 111.81 105.14
l-Glutamic acid 0.996 1.91 2.93 26.47 3.69 5.63 18.47 118.35 145.97 109.48
l-Lactic acid 0.992 1.34 4.93 18.97 1.43 4.30 17.93 103.81 79.26 107.18
Succinic acid 0.997 2.51 4.28 19.51 2.20 4.59 19.92 100.68 151.24 97.04
d-Glucose 0.996 1.92 2.72 3.86 2.25 2.69 3.74 96.36 101.98 100.45
a: Lowest r2 value across three calibration sets during validation; b: Mean recovery of three QC levels.
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2.2.4. Recovery and Matrix Effect
For TCA cycle intermediates, the recoveries are between 73 to 137% in serum, 50 to 172% in
tissue (liver) (except 250% in cis aconitic acid), and 94 to 120% in cell, with worthy repeatability at
all three (low, medium, and high) concentrations levels. The results of recovery obtained at each QC
levels in serum, cell, and tissue are given in supplementary below for further reference. However, the
Coefficient of Variance of recoveries at these three concentration levels was within 17% in serum, cell,
and tissue (murine liver), except for pyruvic acid, succinic acid, and cis aconitic acid with CV 22%, and
oxo-glutaric acid and aspartic acid with CV 50% in tissue (murine liver) (Table 2). The result data are
available in Supplementary Table S1.
The matrix effects were within −2 to 2 (less than 1 indicates ion suppression and more than
1 indicates ion enhancement) for most TCA Cycle intermediates in serum, cell, and tissues at the
HQC level. At MQC level values that were within the range of −2 to 2 for cell, serum, and some
metabolites in tissue, except within 3 (serine, lactic acid), within 4 (cis-aconitic acid, isocitric acid). At
LQC level values within the range of −2 to 2 for cell, some metabolites in serum and some metabolites
in tissue, except within the range of 5 in serum (glycine, Alanine, l-aspartic acid, l-Serine, l-Glutamine,
l-Glutamic acid, l-Lactic acid, and Malic acid) and 5 to 10 in tissue (l-Serine, l-Glutamine, l-Glutamic
acid, l-Lactic acid, Fumaric acid, Succinic acid, Malic acid, and Citric acid). To reduce the matrix
effect, used individual isotope-labeled internal standards for respective each individual TCA cycle
intermediate analyte. In the present work, 14 isotopic labeled internal standards were used for 16 TCA
cycle intermediates. The result data are available in Supplementary Table S1.
2.2.5. Stability
The stock solutions and working solution of TCA cycle intermediates were freshly prepared
during individual LC-MS/MS runs. Though, the stability was assessed at the HQC and LQC level
by storing the TCA cycle intermediates at −20 ◦C for seven days and subsequently carrying out the
analysis. During the storage, no loss of analyte was observed, because the degradation was within 15%
in stock and working solution. This is in harmony with work that was done by Keevil and colleagues,
reporting that citric acid was stable at −20 ◦C for 30 days [3]. The autosampler stability was assessed at
the HQC and LQC level by storing the extracted sample at 4 ◦C for 48 h. During the storage at 4 ◦C for
48 h, no loss of analyte was observed, because the degradation was within 15% in extracted sample.
The CV (%) value was <10% for analyte in this study (Table 3). Cell and tissue are available in a wide
range of species, so it is difficult to identify the ideal species for long term in matrix and freeze thaw
stability experiment. That’s why not presented here.
Table 3. Results of stability for stock solution, working solution, and autosampler of TCA
cycle intermediates.
Analyte Stock Solution Stability, % working Solution Stability, % Autosampler Stability (%)
HQC LQC HQC LQC HQC LQC
cis-Aconitic acid 89.13 90.01 87.52 91.02 88.28 89.23
Citric acid 90.12 95.01 91.05 96.12 91.29 94.35
Fumaric acid 100.20 94.25 101.39 95.01 99.80 93.91
Isocitric acid 109.62 111.47 108.52 114.23 112.59 114.80
Malic acid 97.34 86.01 98.10 86.50 98.64 85.56
Pyruvic acid 87.23 98.12 87.01 96.52 86.77 97.81
Oxoglutaric acid 98.99 91.23 96.52 90.34 97.90 89.36
Glycine 110.52 87.24 109.34 87.52 111.83 85.92
l-Alanine 89.25 113.24 89.34 112.24 88.04 115.25
l-Serine 90.52 102.34 91.04 101.11 91.85 101.58
l-Aspartic acid 92.00 107.32 93.34 108.00 92.73 108.68
l-Glutamine 86.23 100.12 87.54 99.01 85.45 101.81
l-Glutamic acid 95.12 109.12 93.12 108.92 94.87 107.59
l-Lactic acid 101.52 112.52 102.15 114.19 101.38 115.13
Succinic acid 97.85 112.52 98.14 113.00 98.07 114.61
d-Glucose 91.23 100.12 92.32 101.92 90.22 99.29
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2.2.6. Limit of Detection and Limit of Quantification
We calculated the Limit of detection values of the TCA Cycle Intermediates by means of a
signal-to-noise ratio of 3 (Table 1). The lowest calibration standard (Level 1) with accepted accuracy
and precision was considered as LOQ (Table 1).
2.3. Biological Sample Analysis
The validated method was used for quantification of TCA Intermediate analytes in human serum
QCs (n = 6), plasma NIST SRM, kasumi-1 cell, and murine liver tissue. Figure 3, Figure 4, Figure 5, and
Figure 6 shows the quantified analyte amounts. Lactic acid and glucose micro molar concentrations
were approximately 10–100 times higher in scale compared to the other analytes in serum, plasma, and
murine liver tissue. The concentration found in NIST SRM 1950 (n = 6) of glycine (246.4 µmol/L, Std
Dev: 13.29), l-alanine (302.4 µmol/L, Std Dev: 9.88), and serine (92.9 µmol/L, Std Dev: 2.25) are within
the limit of reference values, i.e., 245 ± 16 µmol/L, Std Dev: 16 for glycine, 300 ± 26 µmol/L, Std Dev:
26 for l-alanine, and 95.9 ± 4.3 µmol/L, Std Dev: 4.3 for serine.
The average concentrations that were obtained from serum samples for citric acid (118.6 ±
1.1 µmol/L) were comparable to previous reports using a quantitative GC–MS assay with the
derivatization of citric acid from normal human sera (102.28 ± 37.5 µmol/L) [19]. Previous
studies confirmed the µmol/L concentration in the serum of 30 healthy individuals for L-alanine
(588 ± 216.6 µmol/L), l-serine (105.4 ± 21.2 µmol/L), and glycine (93.28 ± 19.86 µmol/L) [20] and the
comparative concentration from serum was 621.1± 158.1, 132.2± 15.1, and 199.5± 5µmol/L, respectively.
The kasumi-1 Cell line samples were analyzed and the concentration in one-million cells of
metabolites are as glycine (4.4 µmol), alanine (4.4 µmol), serine (3.0 µmol), aspartic acid (2.6 µmol),
glutamine (1.2 µmol), glutamic acid (15.5 µmol), pyruvic acid (1.3 µmol), lactic acid (2.5 µmol),
fumaric acid (0.14 µmol), succinic acid (0.40 µmol), malic acid (2.6 µmol), oxoglutaric acid (0.55 µmol),
cis-aconitic acid (0.14 µmol), glucose (1.6 µmol), citric acid (3.9 µmol), and isocitric acid (6.3 µmol).
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3. Materials and Methods
3.1. Chemicals, Reagents and Samples
Tricarboxylic acid standards [cis-aconitic acid, citric acid (≥99%), fumaric acid (≥99%), isocitric
acid (≥93%), malic acid (≥99%), pyruvic acid, oxo-glutamic acid (≥99%), glycine, l-alanine, l-serine,
l-aspartic acid, l-glutamine, l-glutamic acid, l-lactic acid, succinic acid (≥99%) and d-glucose] were
purchased from Sigma® (M/s Sigma-Aldrich Company Ltd., Dorset, UK). L-malic acid (13C4, 99%),
citric acid (13C6), l-aspartic acid (U-13C4), l-serine (13C3), l-glutamic acid (13C5), glycine (1,2-13C2),
alpha-ketoglutaric acid (13C5), l-alanine (13C3), l-glutamine (13C5), sodium l-lactate (13C3), d-glucose
(U-13C6), fumaric acid (13C4), succinic acid (13C4), and sodium pyruvate (13C3) was purchased from
M/s Cambridge Isotope Laboratories, Inc. (M/s CK Isotopes Ltd., Leicestershire, UK). LC–MS grade
acetonitrile, formic acid, and methanol were purchased from Sigma (M/s Sigma-Aldrich Company Ltd.,
Dorset, UK). Deionized water (18 MΩ·cm at 25 ◦C) that was used for solution preparation was made
while using a Milli-Q water purification system (Bamstea EASYpure RoDi ultrapure water purification
system, M/s Thermo scientific, Waltham, OH, USA). Precellys 2mL homogenizing tubes with 2.8 mm
c ramic beads and reinforced ube were purchase from M/s VWR International (Helsinki, Finland).
The whole blood from w ich serum was prepared during method optimization and validatio was
obtained from the M/s Finnish Red Cross blood service (Helsinki, Finland). Dr. Emmy Verschuren’s
laboratory kindly donated the urine liver tissue (FIMM, HiLife, Biomedicum 2, University of Helsinki,
Finland). Our research collaborators Dr. Mahesh Tambe donated the Kasumi-1 Cell line samples
(FIMM, HiLife, Biomedicum 2, University of Helsinki, Finland). NIST standard reference material
(SRM) 1950 plasma was purchased from M/s Sigma-Aldrich (Gillingham, UK). All of the biological
samples were stored at −80 ◦C. The details on materials are available in Supplementary Table S1.
3.2. Solution Preparation
The stock solutions for individual metabolite were prepared at a concentration of 10 mg/mL
(except d-Glucose 100 mg/mL). An intermediate solution covering all metabolites with a different
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concentration for individually was prepared in 0.1% formic acid in water. The calibration curve
solutions with 11 Levels were prepared by serial dilution from the intermediate solution in 0.1%
formic acid in water to yield a concentration range of: 6.25 to 6400 ng/mL for malic acid; 11.72 to
12,000 ng/mL for cis-aconitic acid and L-aspartic acid; 29.30 to 30,000 ng/mL for isocitric acid, l-Serine,
and l-Glutamic acid; 122.07 to 125,000 ng/mL for citric acid, oxoglutaric acid, glycine, l-alanine, and
l-glutamine; 527.34 to 540000 ng/mL for L-lactic acid; 976.56 to 1,000,000 ng/mL for d-Glucose; 23.44 to
24,000 ng/mL for fumaric acid and succinic acid; and, 244.14 to 250,000 ng/mL for pyruvic acid. The
QC samples were prepared while using separate stock solutions at high (75% of the upper calibration
curve range), medium (nearby to level 6, around 30–50% of the calibration curve range), low (within
three times the LLOQ), and lower limit of quantification.
An internal standard dilution that was prepared from 14 different stocks. (l-malic acid (13C4),
citric acid (13C6), l-aspartic acid (U-13C4), l-serine (13C3), l-glutamic acid (13C5), glycine (1,2-13C2),
alpha-ketoglutaric acid (13C5), l-alanine (13C3), l-glutamine (13C5), sodium l-lactate (13C3), d-glucose
(U-13C6), fumaric acid (13C4), succinic acid (13C4), and sodium pyruvate (13C3). All of the standard
and internal solutions were protected from light and stored at −20 ◦C. During method development
and validation, these solutions are stable and used. The extraction solvent used was 1% formic acid in
acetonitrile and the second extraction solvent was 1% formic acid in acetonitrile:water (90:10), which
was used for tissue metabolite extraction.
3.3. Sample Extraction
3.3.1. Extraction Protocol for Murine Liver Tissue Samples
Approximately 20 mg of frozen tissue was collected in homogenization tubes (Bertin Technologies,
Montigny-le-Bretonneux, France), with 2.8 mm ceramic (zirconium oxide) beads and 2 mL standard
tube volume. Subsequently, the volume of 20 µL of an internal standard dilution solution was added
to the sample and they were equilibrated on ice for 2 min. Subsequently, 300 µL of an 1% formic acid
in acetonitrile was added and vortexed for 20 s. The tissue samples were homogenized while using a
tissue homogenizer (Bertin Technologies, France) over three cycles of 30 s at 5500 rpm each with a 10-s
pause interval between cycles. After homogenization, the samples were centrifuged at 14,000 rpm for
15 min. at 4 ◦C. Supernatant was loaded into a Waters Ostro 96 well plate 25mg (Part No. 186005518).
The same homogenized steps were repeated with a second extraction solvent (acetonitrile:water, 90:10,
1% formic acid). Collected supernatants were passed through a Waters Ostro 96 well plate 25mg (Part
No. 186005518) using a vacuum, subsequently 110 µL of filtrate was mixed with 400 µL 0.1% formic
acid in water. A volume of 5 µL of was then injected into the LC-MS/MS system.
3.3.2. Extraction Protocol for Serum and Plasma
Approximately 100 µL of serum or plasma loaded into Waters Ostro 96 well plate 25 mg (Part
No. 186005518). A volume of 10 µL of ISTD dilution mix was added into the same plate, followed by
the addition of 300 µL of 1% formic acid in acetonitrile. The plate was filtered while using a vacuum.
Subsequently, 110 µL of filtrate was mixed with 400 µL 0.1% formic acid in water. A volume of 5 µL
was injected into the LC-MS/MS system.
3.3.3. Extraction Protocol for Cell
Approximately, in one-million cells, a volume of 90 µL 0.1% Formic acid in water was added and
vortexed to mix, and 10 µL of ISTD dilution mix was added. Subsequently, 300 µL of 1% formic acid in
acetonitrile was added and vortex to mix. Three cycles of extraction were carried out by vortexing
for two minutes and then sonicating for 1 min. (settings: sweep mode, frequency 37, power 60, no
heating). After this, the samples were centrifuged at 14,000 rpm for 15 min at 4 ◦C. Supernatant were
loaded into Waters Ostro 96 well plate 25 mg (Part No. 186005518) and pass through it using vacuum.
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Subsequently, 110 µL of filtrate was mixed with 400 µL 0.1% formic acid in water. A volume of 5 µL
was injected into the LC-MS/MS system.
3.4. Instrument and Analytical Conditions
Waters Acquity UPLC system coupled to a Xevo-TQS triple quadrupole mass spectrometer
equipped with an electrospray ionization probe (M/s Waters Corporation, Milford, MA, USA). An
Atlantis dC18 (2.0 × 100 mm, 3-µm particles) reversed-phase analytical column from Waters (M/s
Milford, MA, USA) was used as a chromatographic separation column. Gradient elution was carried
out with a flow rate of 0.600 mL/min. while using 0.1% formic acid in water as mobile phase A and
acetonitrile as mobile phase B. The gradient elution was initiated from 100% to 90% of mobile phase A
in 8 min., then 90% to 100% followed from 8 to 8.1 min. and the same is maintained for 11 min. The
column oven and auto-sampler temperatures were set to 40 ± 3 ◦C and 5 ± 3 ◦C, respectively. Positive
and negative ion polarity modes were both used for electrospray ionization. Table 4 provides cone
voltage, collision energy, and the MRM transition. The source-dependent parameters were constantly
maintained throughout analysis, including capillary voltage (3.5 kV), desolvation temperature (500
◦C), desolvation gas flow (600 L/h), cone gas flow (150 L/h), and collision gas flow (0.15 mL/min.).
Nitrogen (purity > 99.9%) and argon (purity 99.998%) were used as the desolvation and collision
gases, respectively. The MRM transition mode was used for the quantification of metabolites with
an individual span time of 0.1 s being taken in their individual MRM transition. The dwell time
was automatically calculated based on the region of the retention time window, the number of MRM
transition, and the number of data points required to form a peak. Mass Lynx 4.1 software used for
data acquisition and integrations. The peak area ratio (area of metabolite/ area of IS) that was used for
quantification of the metabolites and weighting factor of 1/x2 was used in the fitting of linear least
squares calibration curves.
Table 4. Compound dependent parameters.
Analyte Mass transition Cone Voltage (eV) Collision Voltage (V) Ionization Mode
cis-Aconitic acid 172.97 > 128.9 22 8 Negative
Citric acid 191.1 > 110.94 16 10 Negative
Fumaric acid 115.1 > 41.00 & 70.94 32 6 Negative
Isocitric acid 191.1 > 155.00 20 12 Negative
Malic acid 133.1 > 114.91 & 71.00 34 10 Negative
Pyruvic acid 87.16 > 42.96 28 6 Negative
Oxoglutaric acid 145.1 > 100.91 22 6 Negative
Glycine 76.1 > 30.15 20 7 Positive
l-Alanine 90.1 > 44.15 20 10 Positive
l-Serine 106.1 > 60.5 23 7 Positive
l-Aspartic acid 134.15 > 74.05 29 13 Positive
l-Glutamine 147.1 > 130.1 26 8 Positive
l-Glutamic acid 148.1 > 130.1 22 9 Positive
l-Lactic acid 88.97 > 42.96 22 8 Negative
Succinic acid 117.05 > 73.00 22 12 Negative
d-Glucose 179.1 > 88.94 36 4 Negative
3.5. Validation
Validation of the analytical method was performed to verify the reliability of the developed
method for the analysis of a large number of samples. Method validation was carried out
according to the European Medicines Agency (EMA) “guidelines on bioanalytical method validation”
(EMEA/CHMP/EWP/192217/2009 Rev. 1) [21]. Linearity, precision, accuracy, recovery, matrix effect,
stability, limit of detection (LOD), and limit of quantification (LOQ) were evaluated for the developed
method. Quality control (QC) samples at high (75% of the upper calibration curve range), middle
(around 30–50% of the calibration curve range), low (within three times the LLOQ), and lower limit of
quantification concentration levels were prepared by spiking the standard solution in the respective
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homogenized biological matrices (during recovery, matrix effect QC samples at high, middle, and low
levels were spiked in pooled of each matrix type i.e., serum, cell, and tissue) to complete all method
validation experiments. However, these matrices have natural endogenous TCA cycle intermediates,
thus the concentration of the non-spiked samples were subtracted from the concentration of the spiked
samples. Complete validation was carried out for the murine liver tissue and serum. A calibration
curve in aqueous diluent was used for method validation. A system suitability experiment was carried
out by injecting six consecutive injections of middle quality control concentration at the start of method
validation and on every day to check the instrument performance and response reproducibility in
terms of the peak area for each metabolite. The coefficient of variation (CV %) for the system suitability
was within the range of 15%.
3.5.1. Selectivity and Specificity
The selectivity and specificity for individual metabolite was evaluated by serum-spiked samples
(n = 6) with a known amount of standard. The selectivity and specificity evaluated by chromatographic
interferences from other endogenous compounds of the biological matrix present at the retention time
of the target analyte.
3.5.2. Auto-Sampler Carryover
The auto-sampler carryover perform by injecting the highest standard (Level 11) of the TCA cycle
intermediates in the calibration curve followed by blank injections and the lowest standard (Level 1)
and 5% for the internal standard, as per the European Medical Agency guidelines for bioanalysis.
3.5.3. Linearity, Accuracy and Precision
To assess the linearity, the response of the instrument and concentration of TCA cycle intermediates
should be known and evaluated over a specified concentration range. The calibration standards were
prepared in the aqueous solution, because the same calibration standards were used for different
matrices, i.e., serum, plasma, cell, and tissue. The established range of concentration for all of
the analytes of interest allowed for adequate measurement of their normal concentrations present
in the validated matrices based on the values that are given in the Human Metabolome database
(www.hmdb.ca). Eleven calibration concentration levels were used, in addition to the blank sample
and a zero sample (processed with internal standard). The precision and accuracies were assessed
with three injection batches on separate days, including six replicates of QC samples at high, medium,
and low concentrations, along with calibration curve standards. The calibration curve was plotted
by using the peak area response ratios (standard/labeled standard) versus the concentrations of the
individual TCA cycle intermediates. Each calibration curve was statistically evaluated and constructed
while using appropriate regression models, weighing factors, and transformations. For accuracy and
precision, the mean accuracy (%) and coefficient of variance were determined, respectively.
3.5.4. Recovery and Matrix Effect
The recovery efficiencies for each analyzed TCA cycle intermediate were determined by comparing
the responses that were obtained from the spiked QC matrix (serum, cell, and tissue) at high, medium,
and low concentrations that were prepared by spiking with a standard QC at high, medium, and
low concentrations before and after extraction. The matrix effect (percentage of ion suppression or
enhancement of the MS signal) was determined by comparing the response that was obtained from
spiked QC matrix (serum, cell, tissue) at high, medium, and low concentrations that were prepared by
spiking with a standard QC at high and low concentrations against spike in aqua. Since there were
endogenous TCA cycle intermediates, we subtracted the endogenous concentrations from the samples
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that were spiked. This experiment was performed using six replicates. Recovery and Matrix factor at
each QC level in different Matrix was evaluated by the following formula:
Recovery =
Peak area in spiked sample
Peak area in post spike sample
× 100 (1)
Matrix factor =
Peak area in post spiked sample− Peak area in unspiked sample
Peak area in neat aqueous sample
(2)
3.5.5. Stability
The evaluation of stability was carried out to ensure that the steps taken during sample preparation
and sample analysis, as well as the storage conditions, did not affect the concentration of the measured
analyte. The stability of the stock and working solutions were tested with an appropriate dilution,
while taking the linearity and measuring range of the detector into consideration. The stability was
investigated in relation to storage conditions over time periods that were equal to those that were
applied to the actual study samples. The stability of the stock solution and working solutions at −20 ◦C,
and autosampler stability of the processed sample at injector or autosampler temperature (5 ◦C) for 48
h of the TCA cycle intermediates and internal standard were evaluated while using low (a maximum
of three times the LLOQ) and high (close to the ULOQ) QC samples. They were immediately analyzed
after preparation and after the applied storage conditions for 48 h. The QC samples were analyzed
against a calibration curve, which was obtained from freshly spiked calibration standards, and the
obtained concentrations as compared to the nominal concentrations. The mean concentration at each
level should be within ±15% of the nominal concentration.
3.5.6. Limit of Detection and Limit of Quantification
LOD was defined as the bottommost analyte concentrations giving a signal-to-noise (S/N) ratio of
3. The lowest standard concentration (Level 1) with acceptable accuracy and precision is considered to
be LOQ. The test began with the serial dilution of the last extract of the samples.
3.5.7. Comparison with NIST Reference Material
Commercially available standard-reference plasma (NIST SRM 1950) [22] was analyzed using the
proposed validated method (n = 6 replicates) to evaluate the performance of the quantitative method.
The concentration values for glycine, l-alanine, and serine were compared with the given standard
reference values.
3.5.8. Ethic Statement
Blood was procured from Finnish Red Cross Blood Service “punainen risti veripalvelu” (Helsinki,
Finland) under license number 05/2019.
4. Conclusions
We present a comprehensively validated quantitative method for TCA cycle intermediates. The
method was validated for human serum, plasma, kasumi-1 cell, and murine liver tissue, achieving
high precision with the use of specific corresponding 13C isotope internal standards. The method
can be used for high sample flow-through with minimized workload, due to the cost-efficiency, fast
pretreatment, and short chromatography time. The method has the potential to be used in various
research areas, such as nutrition, cancer, biomarker studies for different pathologies, and central carbon
metabolism profiling as augmentation for metabolic flux analysis.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/3/103/s1,
Figure S1: Structure of TCA cycle intermediates; Figure S2: Peak of TCA cycle intermediates; Table S1: List of
Metabolites, Materials, Data of Recovery and Matrix effect.
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